Mutual of America Capital Management LLC Boosts Stock Holdings in BioLife Solutions, Inc. $BLFS

Key Points

• Mutual of America Capital Management LLC increased its stake in BioLife Solutions by 22.2%, acquiring a total of 638,373 shares worth approximately $13.75 million.
• Despite positive revenue of $25.42 million for the last quarter, BioLife Solutions reported an earnings miss with (0.33) EPS, significantly below the consensus estimate of (0.02).
• Analysts have mixed ratings on BioLife Solutions, with a consensus rating of "Moderate Buy" and an average price target of $31.29, following recent changes in analyst coverage.

Mutual of America Capital Management LLC boosted its position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 22.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 638,373 shares of the medical equipment provider's stock after purchasing an additional 115,963 shares during the period. Mutual of America Capital Management LLC owned about 1.33% of BioLife Solutions worth $13,751,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in BLFS. GAMMA Investing LLC raised its stake in shares of BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after buying an additional 663 shares in the last quarter. SG Americas Securities LLC grew its holdings in BioLife Solutions by 21.6% during the first quarter. SG Americas Securities LLC now owns 19,136 shares of the medical equipment provider's stock worth $437,000 after acquiring an additional 3,405 shares during the period. Peregrine Capital Management LLC raised its position in BioLife Solutions by 3.5% in the first quarter. Peregrine Capital Management LLC now owns 364,446 shares of the medical equipment provider's stock worth $8,324,000 after acquiring an additional 12,241 shares in the last quarter. Principal Financial Group Inc. raised its position in BioLife Solutions by 6.2% in the first quarter. Principal Financial Group Inc. now owns 259,488 shares of the medical equipment provider's stock worth $5,927,000 after acquiring an additional 15,241 shares in the last quarter. Finally, Palisade Capital Management LP lifted its holdings in BioLife Solutions by 13.7% in the first quarter. Palisade Capital Management LP now owns 947,085 shares of the medical equipment provider's stock valued at $21,631,000 after acquiring an additional 113,937 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Trading Down 1.5%

NASDAQ:BLFS opened at $27.32 on Friday. The firm has a 50-day moving average price of $25.74 and a two-hundred day moving average price of $23.46. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.55. The company has a market capitalization of $1.31 billion, a P/E ratio of -227.65 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The business had revenue of $25.42 million during the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, equities research analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analysts Set New Price Targets

BLFS has been the topic of a number of recent analyst reports. Stephens began coverage on shares of BioLife Solutions in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Finally, Zacks Research lowered BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.29.

Insider Transactions at BioLife Solutions

In related news, CFO Troy Wichterman sold 1,032 shares of the business's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $27,688.56. Following the completion of the transaction, the chief financial officer owned 184,186 shares of the company's stock, valued at approximately $4,941,710.38. The trade was a 0.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the company's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $28.55, for a total transaction of $21,412,500.00. Following the completion of the transaction, the insider owned 5,957,165 shares in the company, valued at approximately $170,077,060.75. This trade represents a 11.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,768,006 shares of company stock valued at $45,379,833 over the last three months. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.